ViiV pursues FDA nod for HIV 'Trii' combo pill
This article was originally published in Scrip
Executive Summary
ViiV Healthcare is seeking the FDA's blessing to market a single-tablet regimen (STR) of dolutegravir (DTG), abacavir (ABC) and lamivudine (3TC) – sometimes referred to as Trii – as a treatment for HIV-1 infection.